Skip to content

The Impact of Pre-emptive Home Delivery of ORS + Zinc on Treatment for Child Diarrhea

The Impact of Pre-emptive Home Delivery of ORS + Zinc on Treatment for Child Diarrhea: a Cluster Randomized Controlled Trial in Bauchi, Nigeria

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06444633
Enrollment
102650
Registered
2024-06-05
Start date
2024-09-04
Completion date
2026-08-14
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea Toddler

Keywords

Oral Rehydration Salts, Child Diarrhea, Zinc

Brief summary

The aim of this clustered randomized controlled trial is to evaluate whether free and pre-emptive distribution of Oral Rehydration Salts (ORS) and Zinc at home increases the use of ORS to treat diarrhea cases among children under the age of 5 in Bauchi, Nigeria. The primary research questions for the study are: * RQ1a: Does pre-emptive home delivery with free distribution of ORS and zinc coupled with information about the importance of proper treatment (henceforth referred to as "the intervention") result in greater use of ORS to treat child diarrhea (for children under the age of 5) over the 6 months following the deliveries, relative to the status quo (i.e., in the absence of such an intervention)? * RQ1b: Does the intervention result in greater use of ORS to treat child diarrhea (for children under the age of 5) over the 12 months following the deliveries, relative to the status quo? * RQ1.1: How much does the effect of the intervention on use of ORS to treat child diarrhea (for children under the age of 5) change over time? All wards in Bauchi state will be randomly assigned to one of two groups: * treatment, where all households with at least one child under the age of 5 will receive free pre-emptive ORS and zinc co-packs - with two ORS sachets and 10 zinc tablets per child - coupled with information about the importance of proper treatment * delayed-start control, with care as usual during the evaluation period and intervention delivery post evaluation) groups. A total of 1,732 enumeration areas (EAs) will be sampled across all wards for the study period. Within each EA, 20 eligible households will be randomly sampled for surveys during each wave of data collection: baseline, endline wave 1 (over 1-6 months post intervention), and endline wave 2 (over 7-12 months post intervention). The primary outcomes for the study include the use of ORS to treat child diarrhea over 6 months post-intervention, over 12 months post-intervention, and over each month until 12 months post-intervention.

Interventions

BEHAVIORALCommunity Sensitization + Household visit + Information + Free pre-emptive distribution of ORS+Zinc

The intervention will involve the following: 1) The communities will be sensitized on the importance of ORS and Zinc use for the treatment of child diarrhea, by the Clinton Health Access Initiative (CHAI). 2) Campaigners recruited by CHAI will visit each household in their catchment area that contain at child under 5 years old. 3) During the distribution visits, the campaigners will train caregivers on the dangers of diarrhea and the importance of ORS and zinc use, among other things (including how to prepare, use, and store ORS/zinc, benefits of the treatments, recommended health behaviors such as seeking care, and encouraging basic handwashing and hygiene practices). The caregivers will also receive a flyer describing the same information in their local language, for future reference. 4) Campaigners will then distribute two ORS and zinc co-packs (each co-pack contains two sachets of ORS and 10 tablets of zinc) for free for each child under the age of five in the household.

Sponsors

RAND
Lead SponsorOTHER
Clinton Health Access Initiative, Nigeria
CollaboratorOTHER
Innovations for Poverty Action
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Masking description

The enumerator and the outcomes assessor will be masked to the assignment of intervention.

Intervention model description

The study is a parallel, cluster randomized controlled trial, randomizing administrative wards in Bauchi, Nigeria to treatment (receiving pre-emptive, free ORS+Zinc co-packs (2 nos) per child under 5 to households, along with information about proper use of ORS and Zinc for treating child diarrhea) or delayed-start control (receiving intervention after the end of the study period).

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* At least 15 years old * Has at least one child under 5 at baseline * Proficiency in English or Hausa

Exclusion criteria

* Living in a temporary home (nomadic population) * Does not speak English or Hausa * Unable to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
ORS Use (cases in last 4 weeks)1-6 months post interventionSelf-reported ORS use for a case of child diarrhea that occurred within the last 4 weeks.

Secondary

MeasureTime frameDescription
Zinc + ORS use1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionSelf-reported Zinc + ORS use for a case of child diarrhea that occurred within the last 4 weeks.
Antibiotic use1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionSelf-reported antibiotic use for a case of child diarrhea that occurred within the last 4 weeks.
Zinc use alone1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionSelf-reported Zinc use for a case of child diarrhea that occurred within the last 4 weeks.
Time to ORS initiation1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionBinary and count variables; binary coded to 1 if caregiver started treatment on the same day the diarrhea began; count variable truncated to 7 days.
Exposure to unsafe drinking water1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionSelf-reported use of untreated water to prepare ORS for treating diarrhea experienced by a child who is exclusively breastfed.
Willingness to purchase new ORS packets1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionSelf-reported use of ORS, seeking care, and purchase of ORS among households that experienced at least twice as many diarrhea cases as the number of children under 5.
Child mortality; all cause and from diarrhea1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionSelf-reported mortality (all cause and diarrhea) of children under 5 since intervention
Hospitalization from diarrhea1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionSelf-reported hospitalization (all cause and diarrhea) of children under 5 since intervention
Number of diarrhea episodes1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionCount of episodes of diarrhea experienced by children who had at least one case of diarrhea since intervention.
Care seeking outside the home1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionBinary indicator, coded to 1 if caregiver sought care from each type of provider.
Wastage of ORS and zinc packets1-6 months post intervention, 1-12 months post intervention, and each month from 1-12 months post interventionBinary indicator, coded to 1 for each type of wastage (co-packs being lost, co-packs being stolen, co-packs used for non-diarrhea reasons, co-packs given away)

Countries

Nigeria

Contacts

PRINCIPAL_INVESTIGATORZachary Wagner, Ph.D.

RAND

PRINCIPAL_INVESTIGATORStephanie Bonds, Ph.D.

RAND

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026